Cargando…
Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course
Analyses of IGHV gene mutations in chronic lymphocytic leukemia (CLL) have had a major impact on the prognostication and treatment of this disease. A hallmark of IGHV-mutation status is that it very rarely changes clonally over time. Nevertheless, targeted and deep DNA sequencing of IGHV-IGHD-IGHJ r...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186829/ https://www.ncbi.nlm.nih.gov/pubmed/34113563 http://dx.doi.org/10.3389/fonc.2021.640731 |
_version_ | 1783705024161906688 |
---|---|
author | Bagnara, Davide Tang, Catherine Brown, Jennifer R. Kasar, Siddha Fernandes, Stacey Colombo, Monica Vergani, Stefano Mazzarello, Andrea N. Ghiotto, Fabio Bruno, Silvia Morabito, Fortunato Rai, Kanti R. Kolitz, Jonathan E. Barrientos, Jacqueline C. Allen, Steven L. Fais, Franco Scharff, Matthew D. MacCarthy, Thomas Chiorazzi, Nicholas |
author_facet | Bagnara, Davide Tang, Catherine Brown, Jennifer R. Kasar, Siddha Fernandes, Stacey Colombo, Monica Vergani, Stefano Mazzarello, Andrea N. Ghiotto, Fabio Bruno, Silvia Morabito, Fortunato Rai, Kanti R. Kolitz, Jonathan E. Barrientos, Jacqueline C. Allen, Steven L. Fais, Franco Scharff, Matthew D. MacCarthy, Thomas Chiorazzi, Nicholas |
author_sort | Bagnara, Davide |
collection | PubMed |
description | Analyses of IGHV gene mutations in chronic lymphocytic leukemia (CLL) have had a major impact on the prognostication and treatment of this disease. A hallmark of IGHV-mutation status is that it very rarely changes clonally over time. Nevertheless, targeted and deep DNA sequencing of IGHV-IGHD-IGHJ regions has revealed intraclonal heterogeneity. We used a DNA sequencing approach that achieves considerable depth and minimizes artefacts and amplification bias to identify IGHV-IGHD-IGHJ subclones in patients with prolonged temporal follow-up. Our findings extend previous studies, revealing intraclonal IGHV-IGHD-IGHJ diversification in almost all CLL clones. Also, they indicate that some subclones with additional IGHV-IGHD-IGHJ mutations can become a large fraction of the leukemic burden, reaching numerical criteria for monoclonal B-cell lymphocytosis. Notably, the occurrence and complexity of post-transformation IGHV-IGHD-IGHJ heterogeneity and the expansion of diversified subclones are similar among U-CLL and M-CLL patients. The molecular characteristics of the mutations present in the parental, clinically dominant CLL clone (CDC) differed from those developing post-transformation (post-CDC). Post-CDC mutations exhibit significantly lower fractions of mutations bearing signatures of activation induced deaminase (AID) and of error-prone repair by Polη, and most of the mutations were not ascribable to those enzymes. Additionally, post-CDC mutations displayed a lower percentage of nucleotide transitions compared with transversions that was also not like the action of AID. Finally, the post-CDC mutations led to significantly lower ratios of replacement to silent mutations in VH CDRs and higher ratios in VH FRs, distributions different from mutations found in normal B-cell subsets undergoing an AID-mediated process. Based on these findings, we propose that post-transformation mutations in CLL cells either reflect a dysfunctional standard somatic mutational process or point to the action of another mutational process not previously associated with IG V gene loci. If the former option is the case, post-CDC mutations could lead to a lesser dependence on antigen dependent BCR signaling and potentially a greater influence of off-target, non-IG genomic mutations. Alternatively, the latter activity could add a new stimulatory survival/growth advantage mediated by the BCR through structurally altered FRs, such as that occurring by superantigen binding and stimulation. |
format | Online Article Text |
id | pubmed-8186829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81868292021-06-09 Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course Bagnara, Davide Tang, Catherine Brown, Jennifer R. Kasar, Siddha Fernandes, Stacey Colombo, Monica Vergani, Stefano Mazzarello, Andrea N. Ghiotto, Fabio Bruno, Silvia Morabito, Fortunato Rai, Kanti R. Kolitz, Jonathan E. Barrientos, Jacqueline C. Allen, Steven L. Fais, Franco Scharff, Matthew D. MacCarthy, Thomas Chiorazzi, Nicholas Front Oncol Oncology Analyses of IGHV gene mutations in chronic lymphocytic leukemia (CLL) have had a major impact on the prognostication and treatment of this disease. A hallmark of IGHV-mutation status is that it very rarely changes clonally over time. Nevertheless, targeted and deep DNA sequencing of IGHV-IGHD-IGHJ regions has revealed intraclonal heterogeneity. We used a DNA sequencing approach that achieves considerable depth and minimizes artefacts and amplification bias to identify IGHV-IGHD-IGHJ subclones in patients with prolonged temporal follow-up. Our findings extend previous studies, revealing intraclonal IGHV-IGHD-IGHJ diversification in almost all CLL clones. Also, they indicate that some subclones with additional IGHV-IGHD-IGHJ mutations can become a large fraction of the leukemic burden, reaching numerical criteria for monoclonal B-cell lymphocytosis. Notably, the occurrence and complexity of post-transformation IGHV-IGHD-IGHJ heterogeneity and the expansion of diversified subclones are similar among U-CLL and M-CLL patients. The molecular characteristics of the mutations present in the parental, clinically dominant CLL clone (CDC) differed from those developing post-transformation (post-CDC). Post-CDC mutations exhibit significantly lower fractions of mutations bearing signatures of activation induced deaminase (AID) and of error-prone repair by Polη, and most of the mutations were not ascribable to those enzymes. Additionally, post-CDC mutations displayed a lower percentage of nucleotide transitions compared with transversions that was also not like the action of AID. Finally, the post-CDC mutations led to significantly lower ratios of replacement to silent mutations in VH CDRs and higher ratios in VH FRs, distributions different from mutations found in normal B-cell subsets undergoing an AID-mediated process. Based on these findings, we propose that post-transformation mutations in CLL cells either reflect a dysfunctional standard somatic mutational process or point to the action of another mutational process not previously associated with IG V gene loci. If the former option is the case, post-CDC mutations could lead to a lesser dependence on antigen dependent BCR signaling and potentially a greater influence of off-target, non-IG genomic mutations. Alternatively, the latter activity could add a new stimulatory survival/growth advantage mediated by the BCR through structurally altered FRs, such as that occurring by superantigen binding and stimulation. Frontiers Media S.A. 2021-05-25 /pmc/articles/PMC8186829/ /pubmed/34113563 http://dx.doi.org/10.3389/fonc.2021.640731 Text en Copyright © 2021 Bagnara, Tang, Brown, Kasar, Fernandes, Colombo, Vergani, Mazzarello, Ghiotto, Bruno, Morabito, Rai, Kolitz, Barrientos, Allen, Fais, Scharff, MacCarthy and Chiorazzi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Bagnara, Davide Tang, Catherine Brown, Jennifer R. Kasar, Siddha Fernandes, Stacey Colombo, Monica Vergani, Stefano Mazzarello, Andrea N. Ghiotto, Fabio Bruno, Silvia Morabito, Fortunato Rai, Kanti R. Kolitz, Jonathan E. Barrientos, Jacqueline C. Allen, Steven L. Fais, Franco Scharff, Matthew D. MacCarthy, Thomas Chiorazzi, Nicholas Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course |
title | Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course |
title_full | Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course |
title_fullStr | Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course |
title_full_unstemmed | Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course |
title_short | Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course |
title_sort | post-transformation ighv-ighd-ighj mutations in chronic lymphocytic leukemia b cells: implications for mutational mechanisms and impact on clinical course |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186829/ https://www.ncbi.nlm.nih.gov/pubmed/34113563 http://dx.doi.org/10.3389/fonc.2021.640731 |
work_keys_str_mv | AT bagnaradavide posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT tangcatherine posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT brownjenniferr posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT kasarsiddha posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT fernandesstacey posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT colombomonica posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT verganistefano posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT mazzarelloandrean posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT ghiottofabio posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT brunosilvia posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT morabitofortunato posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT raikantir posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT kolitzjonathane posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT barrientosjacquelinec posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT allenstevenl posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT faisfranco posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT scharffmatthewd posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT maccarthythomas posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse AT chiorazzinicholas posttransformationighvighdighjmutationsinchroniclymphocyticleukemiabcellsimplicationsformutationalmechanismsandimpactonclinicalcourse |